StockNews.com Upgrades uniQure (NASDAQ:QURE) to Sell

uniQure (NASDAQ:QURE - Get Free Report) was upgraded by StockNews.com to a "sell" rating in a research note issued on Wednesday.

A number of other research firms have also recently weighed in on QURE. Leerink Partners lifted their target price on shares of uniQure from $26.00 to $44.00 and gave the company an "outperform" rating in a research note on Wednesday, December 11th. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $20.00 and gave the stock a "neutral" rating in a research note on Thursday, December 12th. Cantor Fitzgerald lifted their target price on uniQure from $28.00 to $58.00 and gave the company an "overweight" rating in a research note on Tuesday, December 10th. Guggenheim reiterated a "buy" rating on shares of uniQure in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company raised shares of uniQure from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $40.00.

uniQure Stock Performance

NASDAQ:QURE traded up $0.22 during mid-day trading on Wednesday, hitting $16.13. 959,066 shares of the company traded hands, compared to its average volume of 1,093,868. uniQure has a one year low of $3.73 and a one year high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $786.18 million, a price-to-earnings ratio of -3.25 and a beta of 0.39. The stock's fifty day moving average price is $14.29 and its 200-day moving average price is $9.09.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts' consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analysts' expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Research analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company's stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.74% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of QURE. abrdn plc lifted its position in shares of uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company's stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Franklin Resources Inc. purchased a new position in uniQure in the 3rd quarter worth about $7,360,000. Point72 Asset Management L.P. lifted its holdings in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company's stock valued at $4,816,000 after buying an additional 752,889 shares in the last quarter. FMR LLC boosted its position in uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company's stock valued at $1,728,000 after buying an additional 346,274 shares during the period. Finally, Privium Fund Management B.V. grew its stake in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company's stock worth $3,672,000 after acquiring an additional 104,500 shares in the last quarter. Institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.